136 related articles for article (PubMed ID: 16855376)
1. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.
Sui M; Xiong X; Kraft AS; Fan W
Cancer Biol Ther; 2006 Aug; 5(8):1015-21. PubMed ID: 16855376
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy.
Xiong X; Sui M; Fan W; Kraft AS
Cancer Biol Ther; 2007 Jul; 6(7):1067-73. PubMed ID: 17568189
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy.
Sui M; Dziadyk JM; Zhu X; Fan W
Clin Cancer Res; 2004 Jul; 10(14):4848-57. PubMed ID: 15269161
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.
Serrano MJ; Sánchez-Rovira P; Algarra I; Jaén A; Lozano A; Gaforio JJ
Jpn J Cancer Res; 2002 May; 93(5):559-66. PubMed ID: 12036452
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
Johnson KR; Wang L; Miller MC; Willingham MC; Fan W
Clin Cancer Res; 1997 Oct; 3(10):1739-45. PubMed ID: 9815558
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Zhu K; Gerbino E; Beaupre DM; Mackley PA; Muro-Cacho C; Beam C; Hamilton AD; Lichtenheld MG; Kerr WG; Dalton W; Alsina M; Sebti SM
Blood; 2005 Jun; 105(12):4759-66. PubMed ID: 15728126
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
Smorenburg CH; Sparreboom A; Bontenbal M; Verweij J
Eur J Cancer; 2001 Dec; 37(18):2310-23. PubMed ID: 11720823
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Ling YH; Jiang JD; Holland JF; Perez-Soler R
Mol Pharmacol; 2002 Sep; 62(3):529-38. PubMed ID: 12181429
[TBL] [Abstract][Full Text] [Related]
10. Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy.
Johnson KR; Young KK; Fan W
Clin Cancer Res; 1999 Sep; 5(9):2559-65. PubMed ID: 10499633
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.
Chen H; Landen CN; Li Y; Alvarez RD; Tollefsbol TO
Exp Cell Res; 2013 Mar; 319(5):697-706. PubMed ID: 23333498
[TBL] [Abstract][Full Text] [Related]
12. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.
Chiang CT; Yeh PY; Gao M; Chen CW; Yeh LC; Feng WC; Kuo SH; Hsu CH; Lu YS; Cheng AL
Cancer Lett; 2010 Dec; 298(2):195-203. PubMed ID: 20673698
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Kim HJ; Kim HP; Yoon YK; Kim MS; Lee GS; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Anticancer Drugs; 2012 Mar; 23(3):288-97. PubMed ID: 23422737
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Skoda C; Erovic BM; Wachek V; Vormittag L; Wrba F; Martinek H; Heiduschka G; Kloimstein P; Selzer E; Thurnher D
Oncol Rep; 2008 Jun; 19(6):1499-503. PubMed ID: 18497956
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines.
Perabo FG; Lindner H; Schmidt D; Huebner D; Blatter J; Fimmers R; Müller SC; Albers P
Anticancer Res; 2003; 23(6C):4805-14. PubMed ID: 14981929
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Stagg MP; Fontenot MF; Buller EJ; Rainey JM
Am J Clin Oncol; 2002 Oct; 25(5):523-7. PubMed ID: 12393998
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
19. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
[TBL] [Abstract][Full Text] [Related]
20. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR
Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
